Skip to main content
SpringerLink
Log in

Efficacy of Topical Tacrolimus 0.1% in Active Plaque Morphea

Randomized, Double-Blind, Emollient-Controlled Pilot Study

  • Original Research Article
  • Topical Tacrolimus 0.1% for Active Plaque Morphea
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Background: Tacrolimus, a calcineurin inhibitor, is an immunomodulating and anti-inflammatory drug that inhibits T-cell activation and production of cytokines. The elevated level of cytokines in morphea causes fibroblast proliferation and subsequent overproduction of collagen. Theoretically, tacrolimus could inhibit the pathophysiologic process of morphea.

Objective: To assess whether tacrolimus 0.1% ointment is an effective treatment for active plaque morphea in a double-blind, placebo (petroleum emollient)-controlled pilot study.

Methods: Ten patients with active plaque morphea were included. All patients were treated with tacrolimus 0.1% ointment and with an emollient (petrolatum) on two selected morphea plaques, applied twice daily for 12 weeks. Initial and final assessment included surface area measurements, photography, durometer scores, and clinical feature scores. Adverse reactions were recorded.

Results: The scleroderma plaques treated with topical tacrolimus 0.1% improved, resulting in a significant reduction in durometer and clinical feature scores. Overall, a significant difference could be found between topical tacrolimus and petrolatum with regard to durometer score (p < 0.005) and the clinical feature score (p = 0.019).

Conclusion: In this first double-blind, placebo-controlled pilot study comparing tacrolimus 0.1% ointment with petrolatum in active plaque morphea, tacrolimus 0.1% ointment was shown to be an effective treatment for this condition.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Assmann T, Homey B, Ruzicka T. Applications of tacrolimus for the treatment of skin disorders. Immunopharmacology 2000; 47: 203–13

    Article  PubMed  CAS  Google Scholar 

  2. Zulian F. Systemic manifestations in localized scleroderma. Curr Rheumatol Rep 2004; 6: 417–24

    Article  PubMed  Google Scholar 

  3. Alecu M, Geleriu L, Coman G, et al. The interleukin-1, interleukin-2, interleukin-6 and tumour necrosis factor alpha serological levels in localised and systemic sclerosis. Rom J Intern Med 1998; 36: 251–9

    PubMed  CAS  Google Scholar 

  4. Hasegawa M, Sato S, Nagaoka T, et al. Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma. Dermatology 2003; 207: 141–7

    Article  PubMed  CAS  Google Scholar 

  5. Ihn H, Sato S, Fujimoto M, et al. Demonstration of interleukin 8 in serum samples of patients with localized scleroderma. Arch Dermatol 1994; 130: 1327–8

    Article  PubMed  CAS  Google Scholar 

  6. Ihn H, Sato S, Fujimoto M, et al. Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res 1995; 287: 193–7

    Article  PubMed  CAS  Google Scholar 

  7. Chung L, Lin J, Furst DE, et al. Systemic and localized scleroderma. Clin Dermatol 2006; 24: 374–92

    Article  PubMed  Google Scholar 

  8. Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo Clin Proc 1995; 70: 1068–76

    Article  PubMed  CAS  Google Scholar 

  9. Joly P, Bamberger N, Crickx B, et al. Treatment of severe forms of localized scleroderma with oral corticosteroids: follow-up study on 17 patients. Arch Dermatol 1994; 130: 663–4

    Article  PubMed  CAS  Google Scholar 

  10. Dytoc M, Ting PT, Man J, et al. First case series on the use of imiquimod for morphoea. Br J Dermatol 2005; 153: 815–20

    Article  PubMed  CAS  Google Scholar 

  11. Aragane Y, Kawada A, Maeda A, et al. Disseminated scleroderma of a Japanese patient successfully treated with bath PUVA photochemotherapy. J Cutan Med Surg 2001; 5: 135–9

    Article  PubMed  CAS  Google Scholar 

  12. Kreuter A, Gambichler T, Breuckmann F, et al. Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma. Arch Dermatol 2005; 141: 847–52

    Article  PubMed  CAS  Google Scholar 

  13. Seyger MM, van Den Hoogen FH, de Boo T, et al. Low-dose methotrexate in the treatment of widespread morphea. J Am Acad Dermatol 1998; 39: 220–5

    Article  PubMed  CAS  Google Scholar 

  14. Uziel Y, Feldman BM, Krafchik BR, et al. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr 2000; 136: 91–5

    Article  PubMed  CAS  Google Scholar 

  15. Falanga V, Medsger Jr TA. D-penicillamine in the treatment of localized scleroderma. Arch Dermatol 1990; 126: 609–12

    Article  PubMed  CAS  Google Scholar 

  16. Hunzelmann N, Anders S, Fierlbeck G, et al. Double-blind, placebocontrolled study of intralesional interferon gamma for the treatment of localized scleroderma. J Am Acad Dermatol 1997; 36: 433–5

    Article  PubMed  CAS  Google Scholar 

  17. Kreuter A, Hyun J, Stucker M, et al. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol 2006; 54: 440–7

    Article  PubMed  Google Scholar 

  18. Mancuso G, Berdondini RM. Topical tacrolimus in the treatment of localized scleroderma. Eur J Dermatol 2003; 13: 590–2

    PubMed  Google Scholar 

  19. Mancuso G, Berdondini RM. Localized scleroderma: response to occlusive treatment with tacrolimus ointment. Br J Dermatol 2005; 152: 180–2

    Article  PubMed  CAS  Google Scholar 

  20. Walker JG, Pope J, Baron M, et al. The development of systemic sclerosis classification criteria. Clin Rheumatol 2007; 26: 1401–9

    Article  PubMed  Google Scholar 

  21. Tuffanelli DL. Localized scleroderma. Semin Cutan Med Surg 1998; 17: 27–33

    Article  PubMed  CAS  Google Scholar 

  22. Zachariae H, Bjerring P, Halkier-Sorensen L, et al. Skin scoring in systemic sclerosis: a modification. Relations to subtypes and the aminoterminal propeptide of type III procollagen (PIIINP). Acta Derm Venereol 1994; 74: 444–6

    CAS  Google Scholar 

  23. Kissin EY, Schiller AM, Gelbard RB, et al. Durometry for the assessment of skin disease in systemic sclerosis. Arthritis Rheum 2006; 55: 603–9

    Article  PubMed  Google Scholar 

  24. Seyger MM, van den Hoogen FH, de Boo T, et al. Reliability of twomethods to assess morphea: skin scoring and the use of a durometer. J Am Acad Dermatol 1997; 37: 793–6

    Article  PubMed  CAS  Google Scholar 

  25. Zulian F, Meneghesso D, Grisan E, et al. A new computerized method for the assessment of skin lesions in localized scleroderma. Rheumatology (Oxford) 2007; 46: 856–60

    Article  PubMed  CAS  Google Scholar 

  26. Goto T, Kino T, Hatanaka H, et al. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 1987; 19: 4–8

    PubMed  CAS  Google Scholar 

  27. Brune A, Miller DW, Lin P, et al. Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol 2007; 24: 76–80

    Article  PubMed  Google Scholar 

  28. Simpson D, Noble S. Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. Drugs 2005; 65: 827–58

    Article  PubMed  CAS  Google Scholar 

  29. Rustin MH. The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. Br J Dermatol 2007; 157: 861–73

    Article  PubMed  CAS  Google Scholar 

  30. Bohm M, Frieling U, Luger TA, et al. Successful treatment of anogenital lichen sclerosus with topical tacrolimus. Arch Dermatol 2003; 139: 922–4

    Article  PubMed  Google Scholar 

  31. Matsumoto Y, Yamamoto T, Isobe T, et al. Successful treatment of vulvar lichen sclerosus in a child with low-concentration topical tacrolimus ointment. J Dermatol 2007; 34: 114–6

    Article  PubMed  CAS  Google Scholar 

  32. Virgili A, Lauriola MM, Mantovani L, et al. Vulvar lichen sclerosus: 11 women treated with tacrolimus 0.1% ointment. Acta Derm Venereol 2007; 87: 69–72

    Article  PubMed  CAS  Google Scholar 

  33. Hawk A, English III JC. Localized and systemic scleroderma. Semin Cutan Med Surg 2001; 20: 27–37

    Article  PubMed  CAS  Google Scholar 

  34. Robinson N, Singri P, Gordon KB. Safety of the new macrolide immunomodulators. Semin Cutan Med Surg 2001; 20: 242–9

    Article  PubMed  CAS  Google Scholar 

  35. Kikuchi K, Tagami H. Comparison of the effects of daily applications between topical corticosteroid and tacrolimus ointments on normal skin: evaluation with noninvasive methods. Dermatology 2002; 205: 378–82

    Article  PubMed  CAS  Google Scholar 

  36. Kyllönen H, Remitz A, Mandelin JM, et al. Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol 2004; 150: 1174–81

    Article  PubMed  Google Scholar 

  37. Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998; 111: 396–8

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. Department of Dermatology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, NL-6500 HB, Nijmegen, the Netherlands

    Elisabeth B.M. Kroft, Tamara J. Groeneveld, Marieke M.B. Seyger &  Elke M.G.J. Jong

Authors
  1. Elisabeth B.M. Kroft
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tamara J. Groeneveld
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marieke M.B. Seyger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elke M.G.J. Jong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elisabeth B.M. Kroft.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kroft, E.B., Groeneveld, T.J., Seyger, M.M. et al. Efficacy of Topical Tacrolimus 0.1% in Active Plaque Morphea. Am J Clin Dermatol 10, 181–187 (2009). https://doi.org/10.2165/00128071-200910030-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200910030-00004

Keywords

Search

Navigation